Finance

Lists
GXE:ETR
Lakefront Biotherapeutics NV
26,28 €
+0,54%
(+0,14) 1D
15 ოქტ, 13:17:52 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GXE...
Open
26,06 €
High
26,28 €
Low
26,06 €
Mkt. cap
1,73 მლრდ.
Avg. vol.
602,00
Volume
584,00
P/E ratio
2,90
52-wk high
30,02 €
52-wk low
22,84 €
EPS
9,05 €
No. of employees
196
Open
26,06 €
High
26,28 €
Low
26,06 €
Mkt. cap
1,73 მლრდ.
Avg. vol.
602,00
Volume
584,00
P/E ratio
2,90
52-wk high
30,02 €
52-wk low
22,84 €
EPS
9,05 €
No. of employees
196
News stories
From web sources and news partners
Profile
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. Wikipedia
About Lakefront Biotherapeutics NV
CEOპოლ სტოფელსი | პოლ სტოფელსი
Employees196
Founded1999
Headquarters-
Sector-
Websitelakefrontbio.com
Last report
11 აგვ. 2026
Fiscal period
Q2 2026
0,03 € / -11,50 €
+100,26%beat
Revenue / Est. (EUR)
12,11 მლნ. / 6,13 მლნ.
+97,55%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
71,16 მლნ.
900,82 მლნ.
6,48 მლნ.
12,11 მლნ.
Cost of goods sold
84,73 მლნ.
107,97 მლნ.
35,76 მლნ.
34,67 მლნ.
Cost of revenue
84,73 მლნ.
107,97 მლნ.
35,76 მლნ.
34,67 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34,55 მლნ.
32,29 მლნ.
35,50 მლნ.
22,50 მლნ.
Operating expense
28,10 მლნ.
170,00 ათ.
34,42 მლნ.
20,95 მლნ.
Total operating expenses
112,83 მლნ.
108,14 მლნ.
70,18 მლნ.
55,62 მლნ.
Operating income
-41,67 მლნ.
792,68 მლნ.
-63,70 მლნ.
-43,51 მლნ.
Other non operating income
-51,21 მლნ.
74,15 მლნ.
959,00 ათ.
223,00 ათ.
EBT including unusual items
-221,49 მლნ.
783,16 მლნ.
13,96 მლნ.
2,01 მლნ.
EBT excluding unusual items
-43,59 მლნ.
835,73 მლნ.
-26,04 მლნ.
-14,75 მლნ.
Income tax expense
-17,50 მლნ.
666,00 ათ.
70,00 ათ.
70,00 ათ.
Effective tax rate
7,90%
0,09%
0,50%
3,48%
Other operating expenses
-6,44 მლნ.
-32,12 მლნ.
-1,08 მლნ.
-1,55 მლნ.
Net income
-202,11 მლნ.
782,15 მლნ.
14,49 მლნ.
2,11 მლნ.
Net profit margin
-284,02%
86,83%
223,61%
17,42%
Earnings per share
-0,18
12,27
0,21
0,03
Interest and investment income
9,91 მლნ.
14,94 მლნ.
12,90 მლნ.
12,11 მლნ.
Interest expense
-
-1,03 მლნ.
-
-127,00 ათ.
Net interest expenses
9,91 მლნ.
13,90 მლნ.
12,90 მლნ.
11,98 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,23 მლნ.
800,91 მლნ.
-55,48 მლნ.
-41,99 მლნ.
Gain or loss from assets sale
23,83 მლნ.
-1,06 მლნ.
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები